1. Heavy + light chain analysis to assign myeloma response is analogous to the IMWG response criteria
- Author
-
Benjamin Hebraud, Philippe Moreau, Loïc Renaud, Bertrand Arnulf, Brigitte Kolb, Lionel Karlin, Margaret Macro, Cyrille Hulin, Deborah Desmier, Bruno Royer, Brigitte Pegourie, Aurore Perrot, Cecile Fohrer, Antoine Machet, Denis Caillot, Guillemette Fouquet, Xavier Leleu, Hervé Avet-Loiseau, Eileen M Boyle, Thomas Systchenko, Thomas Dejoie, Thierry Facon, Valentine Richez, Olivier Decaux, Cécile Gruchet, Susanna Schraen, Stephen Harding, Kym I E Snell, Niels Moya, Stéphanie Guidez, Hôpital Claude Huriez [Lille], CHU Lille, University of Birmingham [Birmingham], CIC - Poitiers, Université de Poitiers-Centre hospitalier universitaire de Poitiers (CHU Poitiers)-Direction Générale de l'Organisation des Soins (DGOS)-Institut National de la Santé et de la Recherche Médicale (INSERM), Centre de biologie pathologie [Lille], Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), Hôpital de Hautepierre [Strasbourg], Hôpital de la Milétrie, Centre hospitalier universitaire de Poitiers (CHU Poitiers), Hôpital Côte de Nacre [CHU Caen], CHU Caen, Normandie Université (NU)-Tumorothèque de Caen Basse-Normandie (TCBN)-Normandie Université (NU)-Tumorothèque de Caen Basse-Normandie (TCBN), Service de Médecine interne et immunologie clinique [Rennes] = internal medicine and clinical immunology [Rennes], CHU Pontchaillou [Rennes], hôpital Sud-Rennes, Hôpital Saint-Louis, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Université Paris Diderot - Paris 7 (UPD7), Institut Universitaire du Cancer de Toulouse - Oncopole (IUCT Oncopole - UMR 1037), Université Toulouse III - Paul Sabatier (UT3), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-CHU Toulouse [Toulouse]-Institut National de la Santé et de la Recherche Médicale (INSERM), Hôpital Robert Debré, Hôpital Robert Debré-Centre Hospitalier Universitaire de Reims (CHU Reims), Hôpital Universitaire de Caen, Centre Hospitalier Lyon Sud [CHU - HCL] (CHLS), Hospices Civils de Lyon (HCL), CHU Amiens-Picardie, Centre Hospitalier Universitaire [Grenoble] (CHU), CHU Dijon, Centre Hospitalier Universitaire de Dijon - Hôpital François Mitterrand (CHU Dijon), Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy), Hôtel-Dieu de Nantes, Hôpital Haut-Lévêque [CHU Bordeaux], CHU Bordeaux [Bordeaux], Hôpital Claude Huriez, Université de Lille, Droit et Santé-Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), Service de médecine interne, Université Paris Diderot - Paris 7 (UPD7)-Assistance publique - Hôpitaux de Paris (AP-HP) (APHP), Centre hospitalier universitaire d'Amiens (CHU Amiens-Picardie), Université de Lille, Droit et Santé-Centre Hospitalier Régional Universitaire [Lille] ( CHRU Lille ), Université de Poitiers-CHU de Poitiers-Direction Générale de l'Organisation des Soins (DGOS)-Institut National de la Santé et de la Recherche Médicale ( INSERM ), Centre Hospitalier Régional Universitaire [Lille] ( CHRU Lille ), CHU de Poitiers, Hôpital de la Côte de Nacre, Assistance publique - Hôpitaux de Paris (AP-HP)-Université Paris Diderot - Paris 7 ( UPD7 ), Institut Universitaire du Cancer de Toulouse - Oncopole ( IUCT Oncopole - UMR 1037 ), Université Paul Sabatier - Toulouse 3 ( UPS ) -CHU Toulouse [Toulouse]-Institut National de la Santé et de la Recherche Médicale ( INSERM ), Hôpital Robert Debré-Centre Hospitalier Universitaire de Reims ( CHU Reims ), Centre Hospitalier Lyon Sud [CHU - HCL] ( CHLS ), Hospices Civils de Lyon ( HCL ), Centre hospitalier universitaire d'Amiens ( CHU Amiens-Picardie ), Centre Hospitalier Universitaire [Grenoble] ( CHU ), Centre Hospitalier Universitaire de Dijon - Hôpital François Mitterrand ( CHU Dijon ), and Centre Hospitalier Régional Universitaire de Nancy ( CHRU Nancy )
- Subjects
Adult ,Male ,0301 basic medicine ,Oncology ,Cancer Research ,medicine.medical_specialty ,response evaluation ,[SDV.CAN]Life Sciences [q-bio]/Cancer ,Immunoglobulin light chain ,[ SDV.CAN ] Life Sciences [q-bio]/Cancer ,03 medical and health sciences ,Cohen's kappa ,Monitoring, Immunologic ,Multiple myeloma ,Internal medicine ,Biomarkers, Tumor ,medicine ,Overall survival ,Humans ,Response criteria ,Aged ,Aged, 80 and over ,Immunoassay ,business.industry ,Remission Induction ,Hematology ,Middle Aged ,Prognosis ,medicine.disease ,3. Good health ,Survival Rate ,030104 developmental biology ,Immunology ,Female ,Immunoglobulin Light Chains ,Immunoglobulin Heavy Chains ,business ,heavy + light chain ,Follow-Up Studies - Abstract
IF 2.755; International audience; Automated serum heavy + light chain (HLC) immunoassays can measure the intact immunoglobulins of each light chain type separately. We though to compare HLC assays with electrophoretic techniques in determining International Myeloma Working Group (IMWG) response criteria. 114 myeloma patients from 2 trials were included. HLC measurements were made utilizing archived sera and response assessments compared with those based on electrophoretic analysis at the time of the trials. Assessments at ∼90 days and maximal response were compared as was the power of the 2 techniques for predicting later responses, overall survival, and progression. The kappa statistic indicated good agreement between the 2 methods for determining IMWG response criteria, although HLC measurements might give better predictions of subsequent responses and frequently gave an earlier indication of change. HLC measurements could represent an alternative to electrophoretic techniques in determining IMWG response. Validation with a greater range of patient responses is needed for confirmation.
- Published
- 2017
- Full Text
- View/download PDF